ATTR-CM Education Program

ORDER ID	FIRST NAME	LAST NAME	DISEASE STATE	RESOURCE	STATUS	DELIVERY	ORDER DATE	EST. SHIP DATE

Customer Name

Call to Action

Communication Framework

Timeline

Ask Your Cardiologist

About ATTR-CM

Resource Type	Resource Name(s)	QTY	EST. Ship Date

Ask Your Cardiologist

About ATTR-CM

There Could Be More To Your Heart Failure

Heart Failure with Unresolved Symptoms?
Talk to your provider about ATTR-CM

Living with Transthyretin Amyloid Cardiomyopathy
(ATTR-CM): What You Should Know

Beyond the Diagnosis: Living with Transthyretin
Amyloid Cardiomyopathy (ATTR-CM)

Your Cardiologist

Your Provider

Your Health Care Provider

Your Doctor

Your Physician

Your Heart Failure Specialist

Your Hospitalist

Your Pharmacist

Your Cardiac Care Team

Your Advanced Practice Provider

Your Nurse

Ask Your Provider

About ATTR-CM

Resource Type	Resource Name(s)	QTY
	0 0

Resource Type	Resource Name(s)	QTY
Tear Pad	ATTR-CM Symptoms, How ATTR-CM Affect the Body	1
Tear Pad	ATTR-CM Symptoms, How ATTR-CM Affect the Body	1
	1

Resource Type	Resource Name(s)	QTY
Poster	support	5	>

page 1

page 2

page 3

page 4

page 5

page 6

page 7

page 8

page 1

Quantity

page 2

Quantity

page 3

Quantity

page 4

Quantity

page 5

Quantity

page 6

Quantity

page 7

Quantity

page 8

Quantity

page 1

page 2

page 3

page 4

page 5

page 6

page 7

page 8

page 1

page 2

page 3

page 4

page 5

page 6

page 7

page 8

Page 1

Page 2

Page 3

Page 4

Page 5

Page 6

Page 7

Page 8

Ask Your Cardiologist

About ATTR-CM

Ask Your Cardiologist

About ATTR-CM

Ask Your Provider

About ATTR-CM

^§ Only available for use with HIT-D/MOA

^¶ 99mTc-PYP is not FDA-approved for this use. Please consult individual labeling for risks

^∞∞ Only available for use in QIIR discussions with approved guidance from QIIR implementation guide

^§ Only available for use with HIT-D/MOA

^¶ 99mTc-PYP is not FDA-approved for this use. Please consult individual labeling for risks

^∞∞ Only available for use in QIIR discussions with approved guidance from QIIR implementation guide

WORKFLOW EFFICIENCY

STAFF AWARENESS AND EDUCATION

PATIENT EDUCATION

COMMUNICATION AND SUSTAINABILITY

GAP ANALYSIS AND ANALYTICS

^§ Only available for use with HIT-D/MOA

^¶ 99mTc-PYP is not FDA-approved for this use. Please consult individual labeling for risks

^∞∞ Only available for use in QIIR discussions with approved guidance from QIIR implementation guide

test timeline_p1_1

test timeline_p1_2

test timeline_p1_3

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline3p1_1

test timeline_p3_2

test timeline_p3_3

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline_t3_1

test timeline_t3_2

test timeline_t3_3

oct/nov 2024

test timeline_t4_1

test timeline_t4_2

test timeline_t4_3

oct/nov 2024

test timeline_p1_1_c

test timeline_p1_2_c

test timeline_p1_3_c

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline3p1_1

test timeline_p3_2_c

test timeline_p3_3_c

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline_t1_1_c

test timeline_t1_2_c

test timeline_t1_3_c

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline_t3_1_c

test timeline_t3_2_c

test timeline_t3_3_c

oct/nov 2024

test timeline_t4_1_c

test timeline_t4_2_c

test timeline_t4_3_c

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

^§ Only available for use with HIT-D/MOA

^¶ 99mTc-PYP is not FDA-approved for this use. Please consult individual labeling for risks

^∞∞ Only available for use in QIIR discussions with approved guidance from QIIR implementation guide

Customer Name

Call to Action

Communication Framework

Timeline

Customer Name

Call to Action

Communication Framework

Timeline

Call To Action

Communication Framework

Timeline

§ Only available for use with HIT-D/MOA

¶ 99mTc-PYP is not FDA-approved for this use. Please consult individual labeling for risks

∞∞ Only available for use in QIIR discussions with approved guidance from QIIR implementation guide

test timeline_p1_1

test timeline_p1_2

test timeline_p1_3

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline3p1_1

test timeline_p3_2

test timeline_p3_3

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline_t1_1

test timeline_t1_2

test timeline_t1_3

oct/nov 2024

test timeline_t3_1

test timeline_t3_2

test timeline_t3_3

oct/nov 2024

test timeline_t4_1

test timeline_t4_2

test timeline_t4_3

oct/nov 2024

Pfizer is not responsible for any changes made to resource after final delivery to customer.